An analysis about heterogeneity among cancers based on the DNA methylation patterns

BMC Cancer

Table 3 Clinical characteristics of patients in the training set and testing set

Cancer type	Set	Stage				Age		Follow-up time (month)		Survival status
Cancer type	Set	I	II	III	IV	Mean ± SD	Range	Mean ± SD	Range	Alive	Dead
BRCA	Trainingset	70	224	105	11	56.98 ± 12.98	26–90	31.46 ± 35.58	0–197	174	369
	Testing set	68	228	106	11	57.08 ± 13.26	26–90	31.3 ± 37.32	0–238	168	361
	P value	1^a				0.93^b		0.96^b		0.95^a
COAD	Trainingset	29	67	52	28	64.84 ± 12.77	31–90	33.35 ± 32.72	1–151	40	115
	Testing set	27	61	46	25	64.86 ± 13.77	34–90	32.99 ± 27.68	2–143	40	115
	P value	1^a				0.99^b		0.92^b		1^a
ESCA	Trainingset	20	50	40	16	62.52 ± 11.48	42–86	17.81 ± 14.96	1–69	39	54
	Testing set	22	52	39	16	62.31 ± 12.32	27–90	17.96 ± 18.07	1–124	39	54
	P value	0.99^a				0.91^b		0.95^b		1^a
LUAD	Trainingset	129	57	41	12	65.1 ± 10.25	40–87	30.1 ± 30.96	1–236	86	151
	Testing set	126	60	37	13	65.16 ± 10.04	33–88	30.18 ± 30.13	1–242	86	148
	P value	0.96^a				0.95^b		0.98^b		0.92^a
LUSC	Trainingset	92	70	31	5	67.6 ± 8.87	44–90	33.21 ± 31.36	1–157	83	109
	Testing set	85	70	30	4	67.56 ± 8.6	40–85	32.87 ± 32.26	1–177	81	108
	P value	0.98^a				0.96^b		0.92^b		1^a
PAAD	Trainingset	11	77	3	4	64.73 ± 11.37	40–85	19.06 ± 14.41	1–77	50	43
	Testing set	12	76	4	4	64.84 ± 10.61	35–88	19.07 ± 16.96	1–92	50	43
	P value	1^a				0.95^b		1^b		1^a
UCEC	Trainingset	131	20	52	13	64.21 ± 11.33	33–90	33.31 ± 28.82	1–229	38	180
	Testing set	133	23	49	11	64.22 ± 11.08	31–90	33.2 ± 28.08	1–189	38	178
	P value	0.92^a				1^b		0.97^b		1^a

ISSN: 1471-2407